S
LXRX icon

SignatureFD’s Lexicon Pharmaceuticals LXRX Stock Holding History

SignatureFD’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-388
Closed -$287 – 3389
2024
Q4 		$287 Sell
388
-786
-67% -$947 ﹤0.01% 3196
2024
Q3 		$1.84K Hold
1,174
– – ﹤0.01% 2856
2024
Q2 		$1.97K Hold
1,174
– – ﹤0.01% 2758
2024
Q1 		$2.82K Sell
1,174
-437
-27% -$939 ﹤0.01% 2706
2023
Q4 		$2.46K Buy
+1,611
New +$1.92K ﹤0.01% 2710
2014
Q3 		– Sell
-1,857
Closed -$21K – 824
2014
Q2 		$21K Hold
1,857
– – 0.01% 354
2014
Q1 		$22K Hold
1,857
– – 0.01% 310
2013
Q4 		$23K Buy
+1,857
New +$29.5K 0.01% 333

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SignatureFD's LXRX Position: Q1 2025 in Review

SignatureFD sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 388 shares — an estimated $287 sold.

SignatureFD first reported a position in LXRX in Q4 2013 and held it in 8 quarters. The position peaked at $23K in Q4 2013. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

  • SignatureFD reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • SignatureFD sold 388 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $287.
  • SignatureFD first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • SignatureFD's Lexicon Pharmaceuticals position peaked at $23K in Q4 2013.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.